Report Library
All Reports
Radioligand Therapy (RLT): Current Advances and Future Horizons
November 17, 2026
Radioligand therapy (RLT) is now an established commercial category, though its growth is concentrated in Pluvicto while the other approved agents plateau or decline, and the next wave moves from beta to alpha emitters. This report traces RLT from the first X-ray in 1895 and the first targeted radionuclide therapy in the 1980s through Lutathera in 2017 and Pluvicto in 2022, to this year’s US approval of Pluvicto in hormone-sensitive prostate cancer (PSMAddition) and the first generic Lutathera equivalents, Bexlutry and Bravnetsa. Global sales are forecast to grow from about $1B in 2022 to about $8.9B in 2033, with Pluvicto reaching $5.6B (roughly two-thirds of the growth) while Lutathera plateaus at about $0.9B under generic entry and Xofigo declines. It covers how RLT is moving into earlier prostate settings and how alpha emitters are advancing, led by ACTION-1, the first positive Phase III for an alpha-emitting RLT in NETs. It also looks at the push beyond prostate and NETs, where Phase III trials exist only in kidney (LUTEON), brain (IPAX BrIGHT) and blood cancers (IRIS WaM, AIM-300), and at the next wave of innovation in novel targets, isotopes, combinations and dosimetry. We also look at the barriers to wider use, from isotope supply and the safety profile of SSTR- and PSMA-targeted agents to limited treatment infrastructure, and at three recent FDA complete response letters that all cited manufacturing or facility issues rather than clinical data.
| Disease Group Covered: | Oncology |